The demonstrated synergistic effects induced by BET inhibition and PARP inhibition in vitro led to the evaluation of the therapeutic efficacy of BMN673 and JQ1 as monotherapies or in combination in SCLC xenograft models. The gene discussed is PARP1; the disease is small cell lung carcinoma.